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Abstract
Background Messenger RNA (mRNA) expression levels
in blood cells are important in disease diagnosis, prognosis
and biomarker discovery research. Accurate measurements
of intracellular mRNA levels in blood cells depend upon
several pre-analytical factors, including delays in RNA
extraction from blood after phlebotomy. Dramatic changes
in mRNA expression levels caused by delays in blood
sample processing may render such samples unsuitable for
gene expression analysis.
Objectives This study was conducted to evaluate a blood
collection tube, cell-free RNA-BCT (RNA-BCT), for its
ability to stabilize mRNA expression level in blood cells
post-phlebotomy using indicator mRNAs in reverse tran-
scription quantitative real-time PCR (RT-qPCR) assays.
Methods Blood samples from presumed healthy donors
were drawn into both RNA-BCT and K3EDTA tubes and
maintained at room temperature (18–22 C). The samples
were processed to obtain white blood cells (WBCs) at days
0, 1, 2 and 3. Total cellular RNA was extracted from
WBCs and mRNA concentrations were quantified by RT-
qPCR for glyceraldehyde-3-phosphate dehydrogenase
(GAPDH), c-fos, and p53 transcripts.
Results While blood cells isolated from K3EDTA tubes
showed significant changes in cellular mRNA
concentrations for GAPDH, c-fos, and p53, these mRNAs
concentrations were stable in blood drawn into RNA-BCT.
Conclusion The reagent in the RNA-BCT device stabi-
lizes cellular mRNA concentrations for GAPDH, c-fos and
p53 for at least three days at room temperature.
Key Points
A specialized blood collection device, cell-free RNA
BCT (RNA-BCT) is investigated for its ability to
stabilize RNA in intact blood cells at room
temperature post-phlebotomy.
The RT-qPCR-based analysis is carried out to study
the expression levels of GAPDH, c-fos and p53
mRNA of neutrophils isolated from blood samples
collected in K3EDTA and RNA-BCT devices.
Results indicate that expression levels of these
mRNAs are stable in neutrophils obtained from
RNA-BCT blood for up to 3 days at room
temperature as compared to the neutrophils obtained
from K3EDTA blood.
1 Introduction
Messenger RNA (mRNA) profile of a cell reveals real time
activity of that cell and provides useful information in disease
diagnosis, prognosis or in biomarker discovery [1–4]. Pro-
filing of cellular mRNA expression patterns has been done by
use of microarrays, reverse transcription quantitative real-
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time PCR (RT-qPCR) and molecular beacons [1–6]. Many of
these studies have relied on comparison between affected and
unaffected tissue samples. However, tissue biopsies often
require highly invasive procedures that may not be readily
available. As an alternative, researchers have explored using
human peripheral blood cells as a source material for gene
expression profiling, which are readily available via a rela-
tively noninvasive procedure [2, 7].
Blood samples in collection devices present some
inherent challenges to the genetic profiling of stored blood
cells. Post-phlebotomy, ex vivo blood cells are vulnerable
to metabolic stress due to the lack of glucose and oxygen
during sample storage [8]. As such, certain mRNAs may be
up-regulated unintentionally while others may be degraded.
The primary aim of accurate gene profiling should be to
prevent or mitigate changes to ex vivo mRNA expression
patterns that may occur during blood sample handling prior
to the extraction of mRNA [9, 10]. Methods for isolation of
blood cells often include density-gradient centrifugation
for which equipment is frequently beyond the scope of a
typical clinical setting. This limitation may require that
samples be sent out to an external facility, which further
delays the process and alters mRNA profiles [7].
The above challenges emphasize the importance of
implementing a blood collection device that is capable of
stabilizing mRNAs and their expression at the time of a
blood draw. This may be accomplished by stabilizing cells
immediately, during storage in the tube and minimizing the
time elapsed from blood cell harvest to white blood cell
(WBC) isolation and RNA extraction. Reliable mRNA
expression profiles in blood cells depend on effectively
overcoming post-phlebotomy changes by inhibiting cellu-
lar metabolism and RNase activity.
Blood collection technologies, including PAXgene
(PreAnalytiX) and Tempus (Applied Biosystems) have
been designed to inhibit RNase and metabolic activities by
lysing blood cells at the point of blood collection and
thereby stabilizing the mRNA expression profile [10–12].
However, there are some associated drawbacks when using
these blood collection devices. During total cell lysis, ret-
iculocytes release substantial amounts of a- and b-globin
mRNA. The presence of excessive amounts of globin
mRNA decreases RT-qPCR detection sensitivity of lower
abundance mRNA transcripts and increases signal variation
on microarrays [13, 14]. To circumvent these problems,
additional methods are performed to reduce globin mRNA
from whole blood RNA samples obtained using PAXgene
or Tempus blood collection devices [15]. These additional
globin depletion steps are reportedly inefficient and require
additional costs and resources [16]. These RNA stabilizing
devices are also not useful when RNA expression profile of
a subset is to be investigated because all WBCs are lysed at
the point of phlebotomy. Furthermore, another significant
disadvantage of these RNA stabilizing devices is their
inability to utilize technologies such as molecular beacon
technology, where intact cells are required to visualize the
gene-specific fluorescence staining by histology or by flow
cytometry.
An ideal blood collection device for genetic profiling
would maintain blood cells intact while stabilizing mRNA
expression after the blood draw. Such a device would allow
investigators to isolate WBCs by widely used methodolo-
gies without compromising the original gene expression
profile and to utilize stabilized intact cells in gene
expression profiling using technologies which require
intact cells such as molecular beacon technology. Cell-free
RNA BCT (RNA-BCT) is a blood collection device
known to stabilize cell-free RNA in blood during storage
and shipping at room temperature for 3 days [17–19]. This
study is undertaken to investigate the ability of the RNA-
BCT device to stabilize mRNA in intact blood cells during
room temperature storage for 3 days using mRNAs for
glyceraldehyde-3-phosphate dehydrogenase (GAPDH),
c-fos and p53 as indicators. These genes are chosen based
on their post-phlebotomy responses; GAPDH as a house-
keeping gene, c-fos as a fast acting upregulated oncogene
and p53 as a downregulated tumor suppressor gene.
2 Materials and Methods
2.1 Recruitment of Blood Donors
Anonymous volunteer blood donors were recruited from
Streck, Inc., Omaha, NE, USA. The study was approved by
the institutional review board of the Methodist Hospital,
Omaha, NE, USA and informed consent was obtained prior
to the blood draw. Donors were both male and female and
presumed to be healthy. All donor samples were drawn by
venipuncture.
2.2 Blood Collection
Blood samples were collected from six donors. From each
donor, blood was drawn into four 10 mL K3EDTA tubes
(BD Vacutainer, Becton Dickinson, Franklin Lakes, NJ,
USA) and four 10 mL Cell-Free RNA BCT (Streck Inc.,
Omaha, NE, USA). Blood samples were mixed immedi-
ately after the draw by inverting 10 times and maintained at
room temperature (18–20 C).
2.3 Isolation of Neutrophils from Whole Blood Using
Magnetic Beads
For neutrophil isolation from a whole blood samples, red
blood cells (RBCs) were first removed by lysis. Plasma was
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removed after centrifugation at 350 9 g for 10 minutes and
the remaining buffy coat/RBC layer was treated with a red
cell lysis buffer (150 mM ammonium chloride, 1 mM
EDTA, pH 7.2) in a 1:2 ratio (blood:RBC lysis buffer), for
20 minutes at room temperature. Following centrifugation at
350 9 g for 10 minutes, the cell pellets were suspended in
isotonic phosphate buffered saline (PBS) containing 0.1 %
BSA. Cell counts were determined using a Sysmex KX-21
Hematology Analyzer (Sysmex, Kobe, Japan). The WBC
suspension was treated with CD15 MicroBeads to isolate
neutrophils following the manufacturer’s protocol (Miltenyi
Biotec, Inc., Auburn CA, USA). Briefly, 5 lL MicroBeads
suspension was added for every 107 cells and incubated for
45 minutes at 4 C. A QuadroMACS Separation Unit
(Miltenyi Biotec) was used that was capable of performing
four simultaneous magnetic isolations. The unit was fitted
with MACS LS Separation Columns and the cell suspensions
were applied to the columns, wherein the MicroBead-bound
cells were retained. The columns were washed with PBS and
then the magnetic field was removed before elution with two
1 mL volumes of PBS. After enumerating the cells, aliquots
of 2 9 106 neutrophils were prepared and frozen at -80 C.
Total cellular RNA was extracted from these neutrophils to
quantify c-fos, GAPDH and p53 mRNAs.
2.4 Total Cellular RNA Isolation
RNA was extracted from neutrophils (2 9 106) using a
commercially available kit, QIAGEN RNeasy FFPE Kit,
(Qiagen, Santa Clarita, CA, USA). The manufacturer’s rec-
ommended protocol was modified for extracting the total
RNA. Steps 1–5, and 7 of the protocol were skipped and RNA
extraction started with step 6 by treatment of a cell suspension
containing 2 9 106 cells with 240 lL of buffer PKD. An
additional step was introduced by incubating the samples at
95 C for 10 minutes. The samples were then cooled by
placing them in an ice-bath for 3 minutes. Step 8 was modi-
fied by increasing the amount of Proteinase K from 10 to
20 lL. In step 9, the first incubation time at 56 C was
extended from 15 minutes to 1 hour. The second incubation
time at 80 C was kept unchanged at 15 minutes. The sam-
ples were eluted in 60 lL sterile nuclease-free water and
stored at -80 C until analysis by RT-qPCR.
2.5 RNA Yield and Purity
RNA yield and purity was detected using NanoDrop ND-
1000 spectrophotometer (NanoDrop Technologies, Wil-
mington, Delaware USA) following manufacture’s’ rec-
ommended protocol.
2.6 RT-qPCR
Primers and hydrolysis probes for the RT-qPCR quanti-
fication of mRNAs for GAPDH, c-fos, and p53 were
purchased from Integrated DNA Technologies (Coral-
ville, IA, USA). Primers and probe for GAPDH mRNA
were prepared as previously described by Cohrs et al.
[20]. Primers and probe for the quantification of c-fos
mRNA were prepared as described by Gan et al. [21].
The primers and probes used for the p53 gene are as
follows: forward primer 50-TCAACAAGATGTTT
TGCCAACTG-30; reverse primer 50-ATGTGCTGTGAC
TGCTTGTAGATG-30; probe 50/56FAM/ATCAACCCA
CAGCTGCACAGGGCAGGTCTT-BHQ. Plasmid DNA
constructs were prepared by cloning a DNA fragment
into Zero Blunt TOPO (Invitrogen, Carlsbad, CA), with
each construct containing a single copy of human c-fos,
GAPDH, or p53 mRNA. The resulting amplicons are 67,
75, and 118 bp long, respectively. These plasmid con-
structs were used to constitute the standard curves. The
highest standard had 300,000 copies in 5 lL which was
serially diluted (10-fold) 5 times to get 30,000, 3,000,
300, 30 and 3 copies per 5 lL. GAPDH and c-fos mRNA
were quantified by 1-step RT-qPCR method using Taq-
Man RNA-to CT
TM 1-step Kit (Applied Biosystems,
Foster City, CA, USA). For GAPDH and c-fos assays
5 lL of RNA (*242–358 ng of total RNA) was used.
The RT-qPCR protocol included a reverse transcription
step at 48 C for 15 minutes, PCR enzyme activation at
95 C for 10 minutes, followed by 45 cycles of dena-
turation at 95 C for 15 s and anneal / extension at 60 C
for 1 minute. p53 mRNA was quantified by 2-step RT-
qPCR method, for which iScriptTM Reverse Transcription
Supermix for RT-qPCR (Bio-Rad Laboratories, Pleasan-
ton, CA, USA) was used for RT step and TaqMan
Universal Master Mix II, with UNG (Applied Biosys-
tems, Foster City, CA, USA) was used for the PCR step.
For p53 cDNA synthesis 2 lL of RNA (*97–143 ng of
total RNA) was used. From total cDNA volume of 20,
5 lL of cDNA was used for qPCR. The RT and PCR
were performed in CFX96TM Touch (Bio-Rad, Pleasan-
ton, CA, USA) and the data were processed using Bio-
Rad CFX Manager software.
2.7 Statistical Analysis
Statistical analysis was carried out using Microsoft Excel
for Office 2007. Analysis was performed using paired, two-
tailed Student’s t test and p \ 0.05 was considered statis-
tically significant.
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3 Results
We evaluated the effect of RNA-BCT versus K3EDTA on
the stabilization of neutrophil mRNA levels in whole blood
samples, stored at room temperature over 3 days. RNA
yield and purity was determined by a spectrophotometric
method. The mRNA levels were determined by RT-qPCR
using gene-specific assays for GAPDH, c-fos and p53.
Each data was averaged from duplicate set of PCR samples
for six donors.
3.1 RNA Yield and Purity
Table 1 shows the effect of storage on RNA yield and
purity in neutrophils obtained from blood collected into
K3EDTA tube and RNA BCT. There was no statistically
significant change in RNA yield in neutrophils obtained
from both tube types over time. According to Table 1,
there was no statistically significant change also in RNA
purity over time as indicated by 260/280 and 260/230
ratios.
3.2 Effect of RNA-BCT Reagent on GAPDH mRNA
Figure 1 shows the effect of K3EDTA tube and RNA-BCT
device on GAPDH mRNA level when blood samples
drawn into the respective blood collection tubes were
stored at room temperature over 3 days. The initial mean
GAPDH mRNA concentration in K3EDTA samples
(Fig. 1a) was 2.39 9 104 copies/1 9 106 neutrophils. This
initial value increased over time by 5.8-, 1.1- and 1.2-fold
at days 1, 2 and 3, respectively. The increase observed at
day 1 was statistically significant (p = 0.01). A similar
initial mean GAPDH mRNA concentration, 2.88 9 104
copies/1 9 106 neutrophils, in RNA-BCT sample (Fig. 1b)
was determined. However, the GAPDH level in neutrophils
obtained from blood samples drawn into RNA-BCT
showed no change at day 1 and a 1.2-fold statistically non-
significant decrease at days 2 and 3 (p values 0.7 and 0.8,
respectively).
3.3 Effect of RNA-BCT Reagent on c-Fos mRNA
Figure 2 shows the effect of two blood collection tubes on
c-fos mRNA level in neutrophils obtained from whole
blood samples. The initial mean c-fos mRNA concentration
in neutrophils obtained from K3EDTA blood (Fig. 2a) was
3.60 9 105 copies/1 9 106 neutrophils. This initial value
increased over time showing 5.9- and 1.4-fold increases at
days 1 and 2, respectively. However, the increases
observed at days 1 and 2 were not statistically significant
(p values 0.08 and 0.5, respectively). At day 3 there was a
slight decrease in c-fos mRNA level in neutrophils isolated
from K3EDTA blood. The initial mean c-fos mRNA con-
centration in neutrophils obtained from RNA-BCT blood
(Fig. 2b) was 6.09 9 104 copies/1 9 106 neutrophils,
which was significantly low compared to initial value for
K3EDTA neutrophils. However c-fos mRNA concentra-
tions in neutrophils obtained from RNA-BCT blood were
relatively stable over time showing 1.7-, 1.5- and 1.8-fold
statistically non-significant increase at days 1, 2 and 3,
respectively with corresponding p values 0.2, 0.1 and 0.2
compared to the initial value.
3.4 Effect of RNA-BCT Reagent on p53 mRNA
Figure 3 illustrates the effects of two blood collection tubes
on p53 mRNA level. The p53 mRNA level in neutrophils
obtained from K3EDTA tubes showed a statistically sig-
nificant decrease over three days. The initial mean p53
mRNA concentration in neutrophils obtained from
K3EDTA blood (Fig. 3a) was 3.20 9 10
5 copies/1 9 106
neutrophils. On days 1, 2 and 3 the p53 expression levels
are decreased by 2.4-, 3.2- and 2.5-fold, respectively. The
Table 1 RNA yield and purity in neutrophils obtained from blood collected into K3EDTA tubes and RNA BCT
Sample type Total RNA yield (lg) 260/280 nm ratio 260/230 nm ratio
Mean ± SD (p) Mean ± SD (p) Mean ± SD (p)
K3EDTA day 0 3.7 ± 0.7 1.9 ± 0.09 1.8 ± 0.51
K3EDTA day 1 3.5 ± 1 (0.77) 1.9 ± 0.06 (1) 1.6 ± 0.27 (0.25)
K3EDTA day 2 2.9 ± 1.4 (0.32) 1.8 ± 0.06 (0.74) 1.6 ± 0.15 (0.63)
K3EDTA day 3 3.6 ± 0.9 (0.81) 1.8 ± 0.11 (0.9) 1.7 ± 0.77 (0.84)
RNA-BCT day 0 2.9 ± 0.5 (0.06) 1.8 ± 0.1 (0.64) 1.32 ± 0.4 (0.26)
RNA-BCT day 1 3.4 ± 0.7 (0.58) 1.8 ± 0.05 (0.80) 1.5 ± 0.3 (0.35)
RNA-BCT day 2 4.3 ± 2 (0.58) 1.8 ± 0.09 (0.43) 1.5 ± 0.3 (0.50)
RNA-BCT day 3 3.7 ± 1 (0.91) 1.7 ± 0.3 (0.43) 1.7 ± 0.1 (0.69)
Total RNA was extracted from 2 9 106 neutrophils and eluted in 60 lL of RNase and DNase free water as described in the Sect. 2. Total RNA
concentration, 260/280 and 260/230 nm ratios was determined using NanoDrop ND-1000 spectrophotometer. All time points in both tube types
were compared against K3EDTA day 0 value. n = 6
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decreases observed on days 1 and 2 were statistically sig-
nificant showing p values of 0.005 and 0.04, respectively.
The p53 mRNA level in RNA-BCT samples (Fig. 3b) were
stable compared to K3EDTA blood samples. The initial
mean p53 mRNA concentration in neutrophils obtained
from RNA-BCT blood was 3.18 9 105 copies/1 9 106
neutrophils. The p53 mRNA levels in neutrophils obtained
from RNA-BCT were relatively stable at all time points
even though there was a slight decrease at day 2 compared
to initial day 0 value (1.2-fold) which was not statistically
significant (p = 0.8).
4 Discussion
Cellular RNA in human peripheral blood cells can be a
valuable source for noninvasive diagnosis and prognosis of
various disease conditions and for new biomarker discov-
ery. In vivo changes in expression levels of specific
mRNAs can provide important information associated with
different disease states. Among the challenges for the
accurate detection of mRNA expression levels in human
peripheral blood cells, are perturbations caused by delays
between phlebotomy and RNA extraction from blood cells
[8]. Therefore, there is a need for a blood collection device
which can stabilize mRNA levels in human peripheral
blood cells at room temperature when RNA extraction
from blood is to be delayed. Previous studies demonstrated
that the reagent cocktail in a RNA-BCT device can stabi-
lize circulating cell-free RNA in whole blood plasma by
preventing cellular RNA release into plasma during sample
storage and shipping [17]. This study is undertaken to
investigate the ability of a RNA-BCT device to stabilize
cellular mRNA level in intact peripheral blood cells using
mRNAs for GAPDH, c-fos and p53 in neutrophils as
markers.
In our experiments, blood drawn into standard
K3EDTA collection tubes showed an increase in GAPDH
Fig. 1 Effect of storage of blood samples on GAPDH mRNA
concentration in neutrophils obtained from K3EDTA tubes (a) or
RNA-BCTs (b). Blood from normal healthy donors were drawn into
K3EDTA tubes and RNA-BCTs and stored at room temperature.
Neutrophils were isolated on days 0, 1, 2 and 3, total RNA extracted,
and mRNA for GAPDH was quantified by RT-qPCR. The GAPDH
mRNA concentration in neutrophils obtained from K3EDTA blood
increased over time compared to initial day 0 value. There was 2.2-,
1.1- and 1.2-fold increases at days 1, 2 and 3, respectively. The
GAPDH mRNA concentration in neutrophils obtained from RNA-
BCTs remained relatively stable over time except for a slight decrease
at days 2 and 3. Error bars indicate SD. n = 6. *p = 0.01
Fig. 2 Effect of storage of blood samples on c-fos mRNA concen-
tration in neutrophils obtained from K3EDTA tubes (a) or RNA-BCTs
(b). Blood from normal healthy donors were drawn into K3EDTA
tubes and RNA-BCTs and stored at room temperature. Neutrophils
were isolated on days 0, 1, 2 and 3, total RNA extracted, and mRNA
for c-fos was quantified by RT-qPCR. The fos mRNA concentrations
in neutrophils obtained from K3EDTA blood showed 3.0 and 1.4-fold
increases on days 1 and 2, respectively as compared to initial day 0
value. On day 3 there was a 1.2-fold decrease compared to the day 0
value. The c-fos mRNA concentration in neutrophils obtained from
RNA-BCT blood was relatively stable. Error bars indicate SD. n = 6
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mRNA level while GAPDH mRNA level in blood drawn
into RNA-BCT remained relatively stable for three days
at room temperature (Fig. 1a). Salway, Godfrey and their
colleagues have also found that GAPDH mRNA con-
centrations increase with time in white blood cells
obtained from non-stabilized whole blood samples [20,
21]. As depicted in Fig. 2a, c-fos mRNA levels in neu-
trophils obtained from blood drawn into K3EDTA blood
increased on day 1 but then decreased on days 2 and 3.
This is similar to the c-fos expression pattern observed
by Rainen et al. [12]. However, c-fos mRNA level of
neutrophils obtained from RNA-BCT blood remained
relatively stable for 3 days at room temperature (Fig. 2b).
Initial c-fos mRNA levels detected in RNA-BCT sample
is lower than the initial c-fos mRNA level detected in
K3EDTA. Earlier studies showed that the up-regulation
of c-fos in peripheral blood cells, obtained from non-
stabilized blood, is very fast and occurs within hours [12,
22, 23]. Our result is consistent with the literature report
as c-fos may have been up-regulated between phlebot-
omy and neutrophil lysis, contributing to the high initial
c-fos mRNA copy numbers in the K3EDTA stored
sample. Conversely the initial c-fos mRNA copy numbers
of RNA-BCT stored samples remained low and possibly
represent the actual value. The mRNA level for p53 in
neutrophils obtained from K3EDTA tube decreases
slowly with time. The expression levels are decreased
1.1-fold on day 2 and 1.4-fold on day 3. This is similar
to the results reported by Rainen et al. [12]. On the
contrary, p53 mRNA level remains relatively stable in
neutrophils obtained from the blood drawn in to the
RNA-BCT device. Our results indicate that chemical
cocktail present in RNA-BCT can stabilize RNA in
peripheral blood cells in a blood sample for 3 days at
room temperature.
Unintended alteration in cellular RNA expression that
may take place between phlebotomy and RNA extraction
can be reduced if blood cells are separated immediately
after blood draw and then the RNA extracted. However,
immediate processing can be challenging when the blood
sample is collected in a remote location and necessary
separation equipment is not available. The new RNA-BCT
device can be used to circumvent these issues. Since the
RNA-BCT device stabilizes cellular RNA in peripheral
blood cells, it is possible to store patient blood samples in
these vacuum blood collection tubes at ambient tempera-
tures for up to 3 days without any major change to RNA
expression profile in blood cells. This may enhance the
clinical utility of cellular RNA in blood samples for diag-
nostic and prognostic assay development and new bio-
marker discovery efforts.
5 Conclusion
Our results indicate that the expression patterns of GAP-
DH, c-fos and p53 genes are stable in the blood samples
collected in the RNA-BCT device. Such stability in RNA
expression is necessary to rely on RNA-based diagnostic
assay results or to accurately develop new RNA-based
biomarkers. Although our study is limited by the number of
donors and genes, this opens up an encouraging possibility
to study the effects on the expression levels of more genes
in the blood samples drawn in RNA-BCT.
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Fig. 3 Effect of storage of blood samples on p53 mRNA concentra-
tion in neutrophils obtained from K3EDTA tubes (a) or RNA-BCTs
(b). Blood from normal healthy donors were drawn into K3EDTA
tubes and RNA-BCTs and stored at room temperature. Neutrophils
were isolated on days 0, 1, 2 and 3, total RNA extracted, and mRNA
for p53 was quantified by RT-qPCR. The p53 mRNA concentration in
neutrophils obtained from K3EDTA blood decreased over time
compared to initial day 0 value. There were 1.1- and 1.3-fold decrease
at days 2 and 3, respectively. The p53 mRNA concentration in
neutrophils obtained from RNA-BCTs remained relatively stable over
time except for a slight decrease at day 1. Error bars indicate SD.
n = 6. * p = 0.04, ** p = 0.005
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